To date, there are no network meta-analyses comparing the impact of as-needed treatments
in asthma, including the single maintenance and reliever therapy (known as “SMART” or …

Background Smoking worsens underlying asthma inflammation and also induces resistance
to inhaled corticosteroids (ICS). Small airways dysfunction measured by impulse …

Asthma is an inflammatory disorder in which the small airways of the lung play an important
role. There is also evidence for the systemic nature of asthma. No current method …

Adding a long-acting muscarinic antagonist (LAMA) is recommended in the guidelines for a
patient with asthma not controlled on inhaled corticosteroid (ICS)/long-acting b-agonist …

OBJECTIVE: To review the available methods of evaluating the small airways disease in
asthma and the therapeutic strategies to achieve better control using emerging extrafine …

Importance Long-acting muscarinic antagonists (LAMAs) are a potential adjunct therapy to
inhaled corticosteroids in the management of persistent asthma. Objective To conduct a …

Objective Many asthma patients remain uncontrolled on inhaled corticosteroids (ICS) and
long-acting beta agonists (LABAs), but guidance for selecting add-on therapies, including …

Background Small airways dysfunction (SAD) is well recognised in asthma, yet its role in the
severity and control of asthma is unclear. This study aimed to assess which combination of …

Long-acting muscarinic antagonists (LAMAs) have a recognised role in the management of
chronic obstructive pulmonary disease. In asthma, muscarinic antagonists (both short-and …

Abstract Globally, a small proportion (5–12%) of asthma patients are estimated to have
severe disease. However, severe asthma accounts for disproportionately high healthcare …